Aligos Therapeutics (NASDAQ: ALGS) announced that it has dosed the first patient in its Phase 2 B-SUPREME study of ALG-000184 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE